iDD Biotech (antibody assets) Overview

  • Status

  • Acquired/​Merged

  • Latest Deal Type

  • Asset Purch.

  • Financing Rounds

  • 1

iDD Biotech (antibody assets) General Information

Description

Antibody therapeutics for the treatment of cancer. The monoclonal antibodies (mAb or moAb) are monospecific antibodies that are made by identical immune cells that are all clones of a unique parent cell, in contrast to polyclonal antibodies which are made from several different immune cells.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Acquirer
Genmab
Primary Office
  • Bâtiment Accinov
  • 317 avenue Jean Jaurès
  • 69007 Lyon
  • France
+33 04 00 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

iDD Biotech (antibody assets) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore iDD Biotech (antibody assets)‘s full profile, request access.

Request a free trial

iDD Biotech (antibody assets) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore iDD Biotech (antibody assets)‘s full profile, request access.

Request a free trial